Progression after molecular targeted agents: Hepatic arterial changes and transarterial chemoembolization in hepatocellular carcinoma

N Matsuda, N Imai, T Kuzuya, K Yamamoto, T Ito… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: The purpose of this study was to determine changes in the hepatic arteries
after treatment with a molecular targeted agent (MTA), and evaluate the safety and efficacy …

Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization

O Matsui - Clinical drug investigation, 2012 - Springer
Transarterial chemoembolization (TACE) is the gold standard of treatment for intermediate-
stage hepatocellular carcinoma (HCC), and involves the administration of cytotoxic drugs …

[HTML][HTML] Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma

AA Haydar, D Mukherji, W Faraj… - Gastrointestinal …, 2014 - ncbi.nlm.nih.gov
BACKGROUND: The combination of systemic antiangiogenic therapy and transarterial
chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma …

Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional …

S Lee, KM Kim, SJ Lee, KH Lee, DY Lee… - Acta …, 2017 - journals.sagepub.com
Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC)
frequently causes feeding artery stenosis or occlusion that may interfere with repeated …

OUTCOME OF TRANSARTERIAL CHEMOEMBOLIZATION IN KOREAN PATIENTS WITH HEPATOCELLULAR CARCINOMA: REFERENCE FOR A PROSPECTIVE …

HY Kim, JW Park, HK Park, SM Woo, JI Choi, HB Kim… - Hepatology, 2010 - journals.lww.com
BACKGROUND: The need for combination therapy with transarterial chemoembolization
(TACE) in unresectable HCC has been raised due to the palliative nature of TACE, and …

Impact of anticancer drugs on the therapeutic efficacy and side effects of hepatic arterial embolization for hepatocellular carcinoma

H Ihira, T Sonomura, A Makitani, K Makitani… - JGH …, 2023 - Wiley Online Library
Abstract Background and Aim Transcatheter arterial chemoembolization (TACE) using
various anticancer drugs is often performed to treat hepatocellular carcinoma (HCC). We …

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

A Sergio, C Cristofori, R Cardin, G Pivetta… - Official journal of the …, 2008 - journals.lww.com
OBJECTIVE Although transcatheter arterial chemoembolization (TACE) is effective in
hepatocellular carcinoma (HCC), it is not considered a curative procedure. Among the …

Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy

C Hsu, PC Liang, S Morita, FC Hu, AL Cheng - Liver Cancer, 2012 - karger.com
Transarterial chemoembolization (TACE) moderately prolongs the survival of patients with
intermediate-stage hepatocellular carcinoma. Molecular targeted therapy (MTT) may …

Chemoembolization in patients with hepatocellular carcinoma

R Lencioni - Liver cancer, 2012 - karger.com
Transcatheter arterial chemoembolization (TACE) is the standard of care for nonsurgical
patients with preserved liver function with large or multinodular noninvasive hepatocellular …

Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international …

M Kudo, JL Raoul, HC Lee, AL Cheng, K Nakajima… - 2018 - ascopubs.org
368 Background: TACE is commonly used for patients (pts) with unresectable HCC, and
appropriate pt selection is important to obtain optimal outcomes. However, there is no …